Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Sioux Nation -- Ignore unavailable to you. Want to Upgrade?

To: Karen Lawrence who wrote (17785)	5/17/2005 11:07:40 PM
From: Wharf Rat	Respond to of 361075

Other than that, how was the play, Mrs. Lincoln? An ally of Duesenberg... virusmyth.net

To: Karen Lawrence who wrote (17785)	5/17/2005 11:28:19 PM
From: TigerPaw	Respond to of 361075

I am shocked. When you hear Peter Duesberg, Ph.D., you should know: Despite his tenure at the University of California, his ideas are rejected by almost 100% of AIDS scientists and doctors. They are not taken seriously. Dr. Duesberg and his followers are not medical doctors; they do not treat patients. As far as we know, there is no doctor in the U.S. or anywhere else who treats patients according to Duesberg's ideas. But Duesberg is an excellent, persuasive public speaker. He knows how to sound reasonable, use humor, and include statements that are true, important, and meaningful to people. He offers an easy, comforting approach to HIV. This is why he has been able to influence people to trust him and reject their doctors' advice. aids.org

To: Karen Lawrence who wrote (17785)	5/17/2005 11:52:24 PM
From: stockman_scott	Read Replies (1) \| Respond to of 361075

Toyota to Make Hybrid in U.S. _____________________________ By The New York Times May 18, 2005 DETROIT - Toyota Motor announced on Tuesday plans to build a hybrid version of its Camry sedan in the United States, the first gas-electric vehicle that the automaker will manufacture outside Japan. Toyota will start building the hybrid Camry in the second half of next year and plans to make about 48,000 of them in the first year of production. That is a healthy volume for an introductory vehicle, particularly a hybrid, and would equal about 11 percent of all Camrys sold in the United States last year. For the most part, Toyota did not discuss the details of its new hybrid program, including specifics about the new Camry's powertrain. But a senior company executive did acknowledge that Toyota had plans to build other hybrids in North America. "This isn't going to be the only vehicle of hybrid derivation that's going to be produced in the United States or in North America," Jim Press, chief operating officer of Toyota's American sales division, said at a news conference Tuesday morning. Mr. Press did not elaborate on when and where additional hybrid manufacturing might take place. Toyota plans to center its American hybrid program at the company's manufacturing complex in Georgetown, Ky., where the new hybrid Camry will be built. As production on the Camry begins, some parts, including the battery, will be manufactured in Japan. Later, Toyota plans to produce more hybrid parts in Kentucky. "There's a very strong commitment to want to localize more and more of these components, and we'll be very active and aggressive in trying to do that," said Gary L. Convis, the Toyota managing officer who oversees the Georgetown plant. nytimes.com